Your browser doesn't support javascript.
loading
Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: a prospective study.
Mantovani, Alessandro; Busti, Fabiana; Borella, Nicolò; Scoccia, Enrico; Pecoraro, Barbara; Sani, Elena; Morandin, Riccardo; Csermely, Alessandro; Piasentin, Daniele; Grespan, Elisabetta; Castagna, Annalisa; Bilson, Josh; Byrne, Christopher D; Valenti, Luca; Girelli, Domenico; Targher, Giovanni.
Afiliación
  • Mantovani A; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Busti F; Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Borella N; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Scoccia E; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Pecoraro B; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Sani E; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Morandin R; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Csermely A; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Piasentin D; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Grespan E; Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Castagna A; Department of Medicine, Section of Internal Medicine, EuroBloodNet Center, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Bilson J; School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Byrne CD; National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospital Southampton, National Health Service Foundation Trust, Southampton, UK.
  • Valenti L; School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Girelli D; National Institute for Health and Care Research Southampton Biomedical Research Centre, University Hospital Southampton, National Health Service Foundation Trust, Southampton, UK.
  • Targher G; Department of Transfusion Medicine, Precision Medicine Lab, Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Cardiovasc Diabetol ; 23(1): 305, 2024 Aug 17.
Article en En | MEDLINE | ID: mdl-39154180
ABSTRACT

BACKGROUND:

The effect of plasma hepcidin concentrations on the long-term risk of developing adverse cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) is unclear.

METHODS:

We followed for a median of 55.6 months 213 outpatients with established T2DM (45.5% women, mean age 69 ± 10 years; BMI 28.7 ± 4.7 kg/m2; median diabetes duration 11 years). Baseline plasma ferritin and hepcidin concentrations were measured with an electrochemiluminescence immunoassay and mass spectrometry-based assay, respectively. The primary study outcome was a composite of all-cause mortality or incident nonfatal cardiovascular events (inclusive of myocardial infarction, permanent atrial fibrillation, ischemic stroke, or new hospitalization for heart failure).

RESULTS:

42 patients developed the primary composite outcome over a median follow-up of 55.6 months. After stratifying patients by baseline hepcidin tertiles [1st tertile median hepcidin 1.04 (IQR 0.50-1.95) nmol/L, 2nd tertile 3.81 (IQR 3.01-4-42) nmol/L and 3rd tertile 7.72 (IQR 6.37-10.4) nmol/L], the risk of developing the primary composite outcome in patients in the 3rd tertile was double that of patients in the 1st and 2nd tertile combined (unadjusted hazard ratio [HR] 2.32, 95%CI 1.27-4.26; p = 0.007). This risk was not attenuated after adjustment for age, sex, adiposity measures, smoking, hypertension, statin use, antiplatelet medication use, plasma hs-C-reactive protein and ferritin concentrations (adjusted HR 2.53, 95%CI 1.27-5.03; p = 0.008).

CONCLUSIONS:

In outpatients with T2DM, higher baseline hepcidin concentrations were strongly associated with an increased long-term risk of overall mortality or nonfatal cardiovascular events, even after adjustment for established cardiovascular risk factors, plasma ferritin concentrations, medication use, and other potential confounders.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Enfermedades Cardiovasculares / Regulación hacia Arriba / Diabetes Mellitus Tipo 2 / Hepcidinas Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cardiovasc Diabetol Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores / Enfermedades Cardiovasculares / Regulación hacia Arriba / Diabetes Mellitus Tipo 2 / Hepcidinas Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cardiovasc Diabetol Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido